PUBLIC COMPANY
saveORGANON
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Sun Pharma stops eye-care drug production at Indian plant amid quality issuesThe cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the company’s quality system.biospace · 14d ago
- Roivant, the 'inveterate drug hunters', enters commercial era with LisrayaCEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.biospace · 1mo ago
- Beyond China: Five other overseas destinations for biopharma dollarsAs geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.biospace · 2mo ago
- Will a ‘reset’ reignite investment in women’s health startups?After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI and a widening definition of what constitutes women’s health could spur…biopharma_dive · 2mo ago
- India’s pharma industry is going global. But can it catch up to China?A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.biopharma_dive · 6mo ago
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.biopharma_dive · 6mo ago
- Lilly to buy startup Ajax in bid for a better JAK drugWorth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.biopharma_dive · 6mo ago
- STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and moreIntellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedemastat · 6mo ago
- Sun Pharma to buy Organon for $11.75B in major portfolio expansionIndian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in 2021. The all-cash deal came in at $14 per share ...endpoints · 6mo ago
comments(0)
5-min edit window · permanent after that